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Cutaneous manifestations in hematologic malignancies, especially in leukemia, are not
common and may be very variable. Here we report a very unusual case of a patient
(female, 70 years old) who was admitted to the hospital in 2016 because of skin lesions
on the face, the trunk of the body and the extremities. She had a history of breast cancer
in the year 2004 (pT1b, pN0, cM0, L0, V0, R0) which had been resected and treated with
adjuvant radiation and chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracile)
as well as psoriasis treated with methotrexate and cyclosporine. Because of mild
cytopenia a bone marrow aspirate/biopsy was performed showing myelodysplastic
syndrome (MDS) with multilineage dysplasia. Cytogenetic review revealed a complex
aberrant karyotype denoting adverse outcome. Simultaneously, a skin biopsy could
confirm leukemic skin infiltration. Consequently, a therapy with azacitidine was started.
After the first cycle the patient developed severe pancytopenia with a percentage of 13%
peripheral blasts (previously 0–2%) as well as fever without evidence for infection which
was interpreted as progressive disease. Therefore, the therapeutic regimen was changed
to a biomodulatory therapy consisting of low-dose azacitidine 75 mg/day (given sc d1-7
of 28), pioglitazone 45 mg/day per os, and all-trans-retinoic acid (ATRA) 45 mg/m²/day
per os. After cycle 1 of this combined biomodulatory therapy the patient showed
hematologic recovery; besides a mild anemia (hemoglobin 11.1 g/dl) she developed
a normal blood count. Moreover, the cutaneous leukemic infiltrates which had been
unaffected by the azacitidine ameliorated tremendously after 2 cycles resulting in a
complete remission of the skin lesions after cycle 6. In conclusion, we report a very
unusual case with cutaneous infiltrates being the first clinical manifestation of hematologic
disease, preceding the development of acute myeloid leukemia. While azacitidine alone
was ineffective, a combined biomodulatory approach resulted in a complete remission
of the cutaneous manifestation.
Keywords: leukemic skin infiltration, myelodysplastic syndrome, acute myeloid leukemia, biomodulatory
treatment, anakoinosis
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INTRODUCTION
Clinical Presentation
In May 2016 a 70-year-old female patient was admitted to the
hospital suffering from multiple skin lesions which primarily
appeared on the chest, sacrum and the face 3 months ago. Topic
as well systemic therapy with (high dose) corticosteroids had
been ineffective in the treatment. The patient also complained
about pain of the big joints (knees, hips). Fever, night sweats
or weight loss were denied. A skin biopsy had already been
performed showing no evidence for malignancy or autoimmune
disease.
Physical examination revealed generalized erythematous
infiltrated papules on the entire integument, multiple ulcers
on both breasts and the back as well as papular erythema
on both cheeks (Figures 1A,B). A broad laboratory work-up
showed no pathologies besides mild leukopenia (leukocytes
3.8/nl), mild anemia (11 g/dl), and a positive ANA titer (1:160).
Re-biopsy of the skin on the right upper arm demonstrated
interface dermatitis consistent with the diagnosis of erythema
exsudativum, drug rash or dermatomyositis. Chest x-ray and
ultrasound of the abdomen showed no pathological findings.
A therapy with topic agents as well as systemic corticosteroids
(prednisolone 1 mg/kg) was (re-)started leading to minimal
improvements.
BACKGROUND
Medical History
In 2004, the patient had been diagnosed with papillary
breast cancer of the left breast [pT1b, pN0 (0/8), sN0
(0/3), cM0, L0, V0, R0] which had been treated with breast
conserving surgery, adjuvant radiation as well as adjuvant
chemotherapy (CMF regimen; 6 cycles of cyclophosphamide,
methotrexate, 5-fluorouracile). Periodic aftercare examinations
showed no evidence for metastatic disease. Due to suspected
dermatomyositis a CT-scan of the thorax and abdomen as well
as a bone scintigraphy were performed in April 2016 without
any pathological finding. Moreover, the patient has a history
of psoriasis vulgaris since 1984, which had been treated with
methotrexate and cyclosporine. Because of arthrosis, the patient
received joint replacement surgery of both knees and the right
hip joint.
DISCUSSION
Diagnosis
Within the next 3 months, the skin lesions showed no
improvement upon therapy. Since the laboratory work-up
still revealed mild cytopenia (leukocytes 2.8/nl, hemoglobin
10.7 g/dl, MCV 81 fl, thrombocytes 153/nl) a bone marrow
biopsy was performed in July 2016 confirming myelodysplastic
syndrome with multilineage dysplasia and ringsideroblasts
(MDS-RS-MLD): hypercellular marrow with dysplasia in
all lineages and 36% ringsideroblasts. Bone marrow blasts
(CD34+) were not increased. Because of the preceding
chemo-/radiotherapy, the diagnosis therapy-related MDS
(t-MDS) was stated. The genetic review revealed a complex
aberrant karyotype involving chromosomes 5, 7, 8, 12, 13,
18, 21, and 22 (Karyotype formula: 45,XX,der(5;7)(5pter-
>5p11::7q22->7q11::5p11->5q11::7q11->7pter)[4];
45,XX,der(5;7)(5pter->5p11::7q22->7q11::5p11->5q11::7q11-
>7pter),der(12;18)t(12;18)(p13;q23)del(12)(p12p13)[2];
45,XX,der(5;7)(5pter->5p11::7q22->7q11::5p11->5q11::7q11-
>7pter),+8,der(12;18)t(12;18)(p13;q23)del(12)(p12p13),ider(13)
(q10)del(13)(q13q22),+21,+22[4]; 46,XX[3]; ISCN:
nuc ish 7cen(D7Z1x2),7q31(D7S486x1),8cen(D8Z2x3),
12p13(3
′
ETV6x1,5
′
ETV6x2)(3
′
ETV6 con 5
′
ETV6x1)[74/100]).
Despite positive ringsideroblasts, no mutation in SF3B1 could
be found. IPSS-R (Revised International Prognostic Scoring
System) (Greenberg et al., 2012) demonstrated high risk disease
denoting adverse outcome.
Simultaneously, another skin biopsy was performed.
Histological work-up in the reference center revealed mixed
perivascular infiltrates consisting of lymphocytes and blasts
with a high proliferation rate based on Ki67 staining; immuno-
histochemically positivity of the blasts for myeloperoxidase
(MPO) and KiM1P could be confirmed while being negative
for CD34 (IHC panel: staining for CD3, CD20, CD34, MPO,
KiM1P). In conclusion, leukemic skin infiltration could be
confirmed.
Leukemic skin infiltrates, also termed leukemic skin (LC),
are defined by infiltrates of the epidermis, dermis, or subcutis
by neoplastic leukocytes (leukemia cells), resulting in clinically
identifiable cutaneous lesions. LCs occur in ∼3% of patients
with acute myeloid leukemia (AML) (Agis et al., 2002), and
less frequently in MDS (Patel et al., 2012); with most frequent
association in AML with acute myelomonocytic and monocytic
differentiation (involvement in up to 50% of patients) (Kaddu
et al., 1999; Pont et al., 2001). Clinical manifestations vary
from erythematous papules to plum-colored plaques and nodules
that may become purpuric and ulcerate. Skin infiltrates can
develop simultaneously, following, or rarely preceding the onset
of systemic leukemia (Su, 1994). The latter, termed “aleukemic
leukemia cutis,” occurs most often in patients who eventually
develop AML. Patients with suspected LC should always undergo
biopsy. But like in our case the diagnosis of LC can be challenging:
Immuno-histochemistry can be very helpful in the process with
MPO resembling a strongmarker formyeloid cells while CD34 or
CD117 remain very often negative (Traweek et al., 1993; Cronin
et al., 2009; Li et al., 2018).
Treatment
After the successful diagnosis of MDS and LC a therapy with
azacitidine (given sc 75 mg/m² d 1–7 of 28) resembling the
established first-line therapy in high risk MDS was started in
September 2016. At the end of cycle 1 the patient developed
severe cytopenia (leukocytes=WBC 0.94/nl, neutrophils 0.27/nl;
Figure 2) with a percentage of 13% peripheral blasts (previously
0–2%) as well as fever without evidence for infection. While
cytopenia alone could be just a common side effect of
azacitidine, the combination of cytopenia, rising peripheral
blasts and diminishing clinical condition of the patient (fever
without evidence for infection) was interpreted as progressive
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FIGURE 1 | Cutaneous leukemic skin infiltrates: Skin lesions on the face (A,C,E) and the back of the left upper arm (B,D,F) are shown. Panels (A,B) represent the
treatment-naive state. Panels (C,D) show the lesions after one cycle of azacitidine and one cycle of combined biomodulatory therapy. Panels (E,F) demonstrate
complete remission of skin lesions after six cycles of biomodulatory treatment.
FIGURE 2 | Blood counts: Blood counts of leukocytes (WBC), neutrophils and platelets are shown. Left y-axis shows values for WBC und neutrophils, right y-axis for
platelets. The shown time period comprises the first cycle azacitidine as well as the first cycle of biomodulatory therapy (day 0 = begin of biomodulatory therapy).
disease refractory to hypomethylating agents (HMA). Due
to rising peripheral blasts transformation to acute myeloid
leukemia (AML) was suspected. Unfortunately, this was not
confirmed by bone marrow biopsy. With very little therapeutic
opportunities outside clinical trials HMA failure is associated
with very poor prognosis (Montalban-Bravo et al., 2018). In this
situation, the therapeutic regimen was discontinued. After initial
cytoreduction with hydroxyurea (500mg bid for 5 days) the
therapeutic regimen was changed to a biomodulatory regimen,
consisting of low-dose azacitidine 75 mg/day (given sc d1-7
of 28), pioglitazone 45 mg/day per os, and all-trans-retinoic
acid (ATRA) 45 mg/m²/day per os, which already had shown
impressive results in chemorefractory AML. Previously five
elderly AML patients had been treated with this approach on a
compassionate-use basis outside of a clinical trial in the absence
of alternative therapeutic options leading to induction of myeloid
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differentiation in leukemia blasts and resulting in molecular
remissions in 3 of 5 patients (Thomas et al., 2015).
After cycle 1 of this combined biomodulatory therapy,
the presented patient showed hematologic recovery. Besides a
mild anemia (hemoglobin 11.1 g/dl), she developed normal
blood counts (Figure 2) with the absence of peripheral blasts.
Moreover, the cutaneous leukemic infiltrates which had been
unaffected by the azacitidine alone ameliorated tremendously
after 2 cycles resulting in a complete remission of the skin
lesions after cycle 6 (Figures 1C–F). Unfortunately, on day 1
of the planned 7th cycle of biomodulatory therapy the patient
showed diminished peripheral blood counts (leukocytes 0.7/nl,
hemoglobin 11.5 g/dl, thrombocytes 67/nl); therapy was stopped
and bone marrow biopsy showed progressive AML (40%marrow
blasts). Genetic work-up showed clonal evolution with complex
aberrant karyotype and two independent mutations in TP53. The
treatment was changed to decitabine 20 mg/m2 (given iv d1-5
of 28). After two cycles of decitabine the patient showed rising
peripheral blasts up to 60%. Decitabine was discontinued (end
of May 2017). A cytoreductive therapy with mitoxantrone iv 10
mg/m2 weekly was started. Despite these changes, the patient
died of progressive disease in June 2017.
Nevertheless, the response to biomodulatory therapy in this
case is very remarkable especially in the context of HMA failure.
Concerning LC treatment strategies usually involve systemic as
well as local therapy (i.e., radiotherapy, total skin electron beam
therapy) (Bakst et al., 2011). Persistent complete remission of LC
upon biomodulatory therapy alone is therefore very noteworthy.
Combined transcriptional targeting of peroxisome-
proliferator-activated-receptor gamma (PPARγ) and the retinoic
acid receptor (RAR) as well as treatment with azacitidine have
been previously shown to induce myeloid differentiation and
inhibit leukemic cell growth (Curik et al., 2012; Tabe et al., 2012;
Faber et al., 2013). The combination of all three drugs probably
leads to a synergistic effect. Since such approaches are also widely
applicable in heterogenic (chemorefractory) metastatic diseases
(Reichle and Vogt, 2008; Hart et al., 2016), the effect can be
explained with the new therapeutic concept of “anakoinosis”
which means reprogramming of communicative networks
(Hart et al., 2015). Anakoinosis means re-establishing of tissue
homeostasis by communicatively reprogramming transcriptional
networks maintained by tumor and adjacent stroma cells.
Therefore, the effects of “anakoinotic” treatments are dependent
on the cellular context and the tumor-bearing organ. In the
presented case the response to treatment was context-dependent
as well (skin vs. bone marrow): it was possible to induce a
persistent complete remission of leukemic skin infiltrates,
while in the bone marrow (BM) “normal” hematopoiesis was
transiently improved resulting in normal blood counts, but
eradication of leukemic (stem) cells failed. In AML it is known
that direct physical crowding of BM by accumulating leukemic
cells does not fully account for hematopoietic failure (Boyd et al.,
2017). In this context, the suppression of BM adipocytes plays an
important role leading to imbalanced regulation of endogenous
hematopoietic stem and progenitor cells, resulting in impaired
myelo-erythroid maturation. PPARγ agonists have shown to
induce BM adipogenesis, which rescues healthy hematopoietic
maturation while repressing leukemic growth (Saiki et al., 2006;
Boyd et al., 2017; Ryu et al., 2018). Targeting of the axis between
adipogenesis und myelo-erythroid maturation might explain the
hematologic improvement in our patient. Although an additional
therapeutic agent had been needed to fully eradicate leukemic
blasts (progressive disease is most likely due to clonal evolution
in the BM), the transient improvement of hematopoiesis shows
the effect of biomodulatory treatment on tissue homeostasis.
CONCLUDING REMARKS
In conclusion, we report a very unusual case with cutaneous
infiltrates being the first clinical manifestation of hematologic
disease, preceding the development of acute myeloid leukemia
and therefore resembling a diagnostic challenge. While
one cycle of azacitidine showed no effect on the skin
lesions, a combined biomodulatory approach resulted in a
complete remission of the cutaneous manifestation. Due to
its efficacy in the shown cases the biomodulatory therapy
is currently investigated within a prospective, randomized,
clinical trial (AMLSG26-16/AML-ViVA EudraCT number
2016-000421-39).
METHODS
All genetics analyses (chromosome banding analysis, FISH
und sequencing) have been performed within clinical routine
diagnostics at MLL (Munich Leukemia Laboratory, Munich,
Germany).
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